Protalix BioTherapeuticsÂ’ PRX-102 Granted Orphan Drug Designation by the European Commission

CARMIEL, Israel, Dec. 27, 2017 -- (Healthcare Sales & Marketing Network) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expr... Biopharmaceuticals, Regulatory Protalix BioTherapeutics, ProCellEx, pegunigalsidase alfa, Fabry disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news